Impact of Drug Metabolism/Pharmacokinetics and its Relevance Considering Traditional Medicine-based Anti-COVID-19 Drug Research

Author:

Hao Da-Cheng1ORCID,Wang Fan2,Xiao Pei-Gen3

Affiliation:

1. Biotechnology Institute, School of Environment and Chemical Engineering, Dalian Jiaotong University, Dalian 116028, China | Institute of Molecular Plant Science, University of Edinburgh, Edinburgh EH9 3BF, UK

2. Biotechnology Institute, School of Environment and Chemical Engineering, Dalian Jiaotong University, Dalian 116028, China

3. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing 100193, China

Abstract

Background: The representative anti-COVID-19 herbs, i.e., Poriacocos, Pogostemon, Prunus, and Glycyrrhiza plants, are commonly used in the prevention and treatment of COVID-19, a pandemic caused by SARSCoV- 2. Diverse medicinal compounds with favorable anti-COVID-19 activities are abundant in these plants, and their unique pharmacological/pharmacokinetic properties have been revealed. However, the current trends in drug metabolism/pharmacokinetic (DMPK) investigations of anti-COVID-19 herbs have not been systematically summarized. Methods: In this study, the latest awareness, as well as the perception gaps regarding DMPK attributes, in the anti- COVID-19 drug development and clinical usage was critically examined and discussed. Results: The extracts and compounds of P.cocos, Pogostemon, Prunus, and Glycyrrhiza plants show distinct and diverse absorption, distribution, metabolism, excretion, and toxicity (ADME/T) properties. The complicated herbherb interactions (HHIs) and herb-drug interactions (HDIs) of anti-COVID-19 Traditional Chinese Medicine (TCM) herb pair/formula dramatically influence the PK/pharmacodynamic (PD) performance of compounds thereof, which may inspire researchers to design innovative herbal/compound formulas for optimizing the therapeutic outcome of COVID-19 and related epidemic diseases. The ADME/T of some abundant compounds in anti-COVID-19 plants have been elucidated, but DMPK studies should be extended to more compounds of different medicinal parts, species, and formulations and would be facilitated by various omics platforms and computational analyses. Conclusion: In the framework of pharmacology and pharmacophylogeny, the DMPK knowledge base would promote the translation of bench findings into the clinical practice of anti-COVID-19 and speed up the anti-COVID-19 drug discovery and development.

Funder

Scientific Research Funds Project of the Liaoning Education Department

China Scholarship Council

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Pharmacology

Reference122 articles.

1. Huang W.; Rao Y.L.; Sun Q.G.; Li C.Y.; Ba Y.M.; Study on medication laws of traditional Chinese medicine of 340 cases of COVID-19 based on data mining. Hainan Yixueyuan Xuebao 2020,26(12),881-888

2. Stukalov A.; Girault V.; Grass V.; Karayel O.; Bergant V.; Urban C.; Haas D.A.; Huang Y.; Oubraham L.; Wang A.; Hamad M.S.; Piras A.; Hansen F.M.; Tanzer M.C.; Paron I.; Zinzula L.; Engleitner T.; Reinecke M.; Lavacca T.M.; Ehmann R.; Wölfel R.; Jores J.; Kuster B.; Protzer U.; Rad R.; Ziebuhr J.; Thiel V.; Scaturro P.; Mann M.; Pichlmair A.; Multilevel proteomics reveals host pertur-bations by SARS-CoV-2 and SARS-CoV. Nature 2021,594(7862),246-252

3. de Wit E.; van Doremalen N.; Falzarano D.; Munster V.J.; SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol 2016,14(8),523-534

4. Yang Y.J.; X.H., E.; Ren, H.W.; He, Y.; Zhou, S.P. Consideration of traditional Chinese medicine in treatment of highly pathogenic human coronaviruses SARS-CoV-2 and SARS-CoV. Chin Tradit Herbal Drugs 2020,51(6),1427-1434

5. Wang C.; Ming H.; Jia W.; Su W.; Zhan L.R.; Luo D.; Yang J.Y.; [Analysis of medication regularity and pharmacodynamic characteris-tics of traditional Chinese medicine treatment in 444 severe cases of COVID-19]. Zhongguo Zhongyao Zazhi 2020,45(13),3007-3012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3